The updated survival data from the IMpower010 trial supports the use of adjuvant atezolizumab for patients with stage II to stage IIIA PD-L1-expressing non-small cell lung cancer. The trial included patients who underwent complete resection followed by one to four cycles of chemotherapy before being randomly assigned to atezolizumab or best supportive care. Results showed a significant DFS benefit for patients with PD-L1 expression on at least 1% of tumor cells. A numerical improvement in OS was also observed in this subgroup. Overall, atezolizumab exhibited a safety profile consistent with prior analyses.
Source link
Adjuvant atezolizumab benefits PD-L1-selected patients with NSCLC
